Skip to main content
. 2013 Nov 22;116(2):395–404. doi: 10.1007/s11060-013-1311-3

Table 1.

Clinical characteristics of AOA, GBMO-STS, GBMO-LTS, and GBM

Characteristic Subgroup 1 P value Subgroup 2 P value Subgroup 3 P value
GBMO-STS (n = 11) AOA (n = 36) GBM (n = 110) GBMO-STS (n = 11) GBMO-LTS (n = 29) GBMO-STS (n = 11)
Age (years)
 Median (range) 41.0 (14–58) 44.0 (30–68) 0.157 52.0 (12–70) 41.0 (14–58) 0.048* 43.0 (17–59) 41.0 (14–58) 0.348
Gender
 Male (%) 6 (54.5) 18 (50.0) 70 (63.6) 6 (54.5) 17 (58.6) 6 (54.5)
 Female (%) 5 (45.5) 18 (50.0) 0.792 40 (36.4) 5 (45.5) 0.789 12 (41.4) 5 (45.5) 1.0
Tumor location
 Temporal (%) 4 (36.4) 9 (25.0) 41 (37.3) 4 (36.4) 10 (34.5) 4 (36.4)
 Frontal (%) 4 (36.4) 15 (41.7) 37 (33.6) 4 (36.4) 11 (37.9) 4 (36.4)
 Parietal (%) 2 (18.1) 5 (13.9) 17 (15.5) 2 (18.1) 4 (13.8) 2 (18.1)
 Occipital (%) 0 (0.0) 1 (2.8) 4 (3.6) 0 (0.0) 0 (0.0) 0 (0.0)
 Insular (%) 1 (9.1) 3 (8.3) 6 (5.5) 1 (9.1) 4 (13.8) 1 (9.1)
 Others (%) 0 (0.0) 3 (8.3) >0.05 5 (4.5) 0 (0.0) >0.05 0 (0.0) 0 (0.0) >0.05
Preoperative epilepsy
 Yes (%) 3 (27.3) 13 (36.1) 0.859 25 (22.7) 3 (27.3) 1.0 5 (20.7) 3 (27.3) 0.791
Preoperative KPS
 Median (range) 80 (60–90) 75 (50–100) 0.768 80 (50–100) 80 (60–90) 0.369 80 (60–100) 80 (60–90) 0.677
Tumor resection
 GTR (%) 6 (54.5) 25 (69.4) 0.583 52 (47.3) 6 (54.5) 0.645 18 (62.1) 6 (54.5) 0.942
Nimustine
 Yes (%) 11 (100.0) 34 (94.4) 1.0# 106 (96.4) 11 (100.0) 1.0# 26 (89.7) 11 (100.0) 0.548#
Radiotherapy
 Yes (%) 11 (100.0) 33 (91.7) 1.0# 102 (92.7) 11 (100.0) 1.0# 28 (96.6) 11 (100.0) 1.0#
Temozolomide
 Yes (%) 7 (63.6) 11 (30.6) 0.105 59 (53.6) 7 (63.6) 0.525 21 (72.4) 7 (63.6) 0.877

KPS Karnofsky performance score, GTR gross-total resection

# Fisher’s exact test

P < 0.05